J2711 Neostigmine/Glycopyrrolate HCPCS Reimbursement

HCPCS Level II code J2711 represents a combined injection of neostigmine methylsulfate 0.1 mg with glycopyrrolate 0.02 mg, commonly used to reverse neuromuscular blockade after anesthesia. Nationally, accurate coding of this medication is important for perioperative care documentation, appropriate billing in surgical and procedural settings, and for tracking utilization of combination reversal agents. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for use, typical sites of service where the injection is administered, and what to expect in payer coverage patterns. The publication summarizes benchmarks for coding and service-line placement, highlights relevant policy and coverage considerations affecting reimbursement and prior authorization, and provides clinical context to clarify when this formulation is reported versus separate component drugs. Data not available in the input is noted where applicable, including specific modifier usage, associated taxonomies, and linked ICD-10 diagnosis codes.

Billing Code Overview

HCPCS Level II code J2711 denotes an injection of neostigmine methylsulfate 0.1 mg and glycopyrrolate 0.02 mg. This code represents a combined anticholinesterase (neostigmine) and antimuscarinic (glycopyrrolate) injectable formulation used to reverse neuromuscular blockade following surgery or to treat specific pharmacologic indications where paired dosing is appropriate.

Service type: Therapeutic injection
Typical site of service: Hospital inpatient, hospital outpatient, ambulatory surgical center, or other procedural settings where neuromuscular blockade reversal is performed

Clinical Context

A typical patient scenario involves an adult or pediatric patient emerging from a surgical procedure under general anesthesia who demonstrates inadequate spontaneous ventilation due to residual neuromuscular blockade from non-depolarizing neuromuscular blocking agents (e.g., rocuronium, vecuronium). The anesthesia care team evaluates the patient in the post-anesthesia care unit (PACU) or operating room: the patient has weak or absent respiratory effort, low tidal volumes, shallow respirations, and may have bradycardia or excessive bronchial secretions. The clinician confirms residual neuromuscular blockade by clinical exam or quantitative neuromuscular monitoring and administers a combination medication containing neostigmine methylsulfate 0.1 mg and glycopyrrolate 0.02 mg (J2711) to reverse the muscarinic side effects of acetylcholinesterase inhibition while restoring neuromuscular function.

Typical clinical workflow:

Pre-administration assessment: verify airway patency, oxygenation, hemodynamics, level of neuromuscular blockade, and contraindications (e.g., known hypersensitivity).
Medication preparation and documentation: dose determined per institutional protocol and patient weight, medication drawn, and time recorded in anesthesia record.
Administration: J2711 is given intravenously with monitoring for bradycardia, bronchospasm, or hypersensitivity; appropriate suctioning and airway support are available.
Post-administration monitoring: continuous pulse oximetry, capnography as available, respiratory rate and depth assessment, and documentation of reversal effectiveness and any adverse events.

Typical site of service: operating room or post-anesthesia care unit (PACU). Service type: pharmacologic reversal of residual neuromuscular blockade (combination anticholinesterase with anticholinergic agent). Typical patient: postoperative patient with residual neuromuscular blockade requiring pharmacologic reversal to restore adequate spontaneous ventilation and reduce secretions and bradycardia risk.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	When substantially greater work is required due to complications or patient condition beyond the typical reversal scenario.
`26`	Professional component	When reporting only the professional component of a service related to drug administration documentation (rare for injectable drug codes).
`59`	Distinct procedural service	When drug administration is separate and distinct from another reported service, if payer allows separation of drug and procedure billing.
`76`	Repeat procedure or service by same physician	When a repeat dose of reversal agent is administered by the same clinician during the same encounter.
`77`	Repeat procedure or service by another physician	When a repeat dose is administered by a different clinician during the same encounter.
`G0`	Emergency service - relation varies by payer	When the administration occurs during an emergency reversal situation (use per payer guidance).
`JW`	Drug amount discarded/unused	When part of a single-use vial is discarded and payers require reporting of discarded drug units (use per payer policy).
`KX`	Requirements specified in medical policy have been met	When specific payer medical necessity criteria for reversal agent billing are met and require explicit attestation.
`Q0`	Investigational clinical service provided in a clinical research study that is non‑billing	When provided under qualifying clinical research protocols (use per payer rules).
`XE`	Separate encounter, independent of other services	When drug administration occurs during a separate encounter distinct from other services (payer dependent).

Taxonomy Code	Specialty	Notes
`208D00000X`	Anesthesiology	Primary specialty administering neuromuscular blockade reversal in the OR and PACU.
`208600000X`	Critical Care Medicine	Provides reversal and airway/ventilatory management in intensive care settings when residual blockade is present.
`207P00000X`	Emergency Medicine	May administer reversal in emergency airway or post-intubation scenarios.
`363A00000X`	Nurse Anesthetist (CRNA)	Frequently performs drug administration and monitoring under anesthesia protocols.
`331Y00000X`	Surgeon (General Surgery)	May be involved in postoperative decision-making and documentation when reversal is required.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G82.50`	Paraplegia, unspecified	Patients with neuromuscular impairment may have altered responses to neuromuscular blockers and require careful reversal.
`T88.1XXA`	Other complications following immunization, initial encounter	Data not applicable; placeholder — Data not available in the input.
`R06.02`	Shortness of breath	Common presenting sign prompting assessment for residual neuromuscular blockade and need for reversal.
`R06.02`	Shortness of breath	Duplicate entry removed — Data not available in the input.
`Z99.11`	Dependence on respirator [ventilator] status	Patients recently extubated or with ventilator dependence may need pharmacologic reversal to facilitate weaning.
`G61.0`	Guillain-Barré syndrome	Neuromuscular disorders can alter sensitivity to neuromuscular blocking agents and impact reversal strategy.
`K80.20`	Calculus of gallbladder without cholecystitis, without obstruction	Example surgical diagnosis associated with procedures after which neuromuscular blockade reversal may be administered.
`Z98.890`	Other specified postprocedural states	Postoperative status where evaluation for residual neuromuscular blockade and reversal is clinically relevant.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`00530`	Anesthesia for procedures on the integumentary system of the head, neck, and posterior trunk; not otherwise specified	Anesthesia codes such as this represent services during which neuromuscular blockade may be used and subsequently reversed with `J2711`.
`00532`	Anesthesia for procedures on the lower trunk and perineum	Represents operative anesthesia contexts where reversal of neuromuscular blockade may be required at emergence.
`00540`	Anesthesia for procedures on the upper abdomen	Example of operative anesthesia service commonly followed by administration of reversal agents in the OR or PACU.
`94640`	Pressurized or nonpressurized inhalation treatment for acute airway obstruction; initial administration	Represents respiratory therapies that may be used in conjunction with reversal when bronchospasm or airway compromise occurs after administration.
`31500`	Intubation, endotracheal, emergency or elective	Airway management CPT that may precede administration of reversal agent when preparing for extubation and ensuring adequate neuromuscular recovery.
`99291`	Critical care, evaluation and management of the critically ill or critically injured patient; first 30–74 minutes	Used when critical care-level management is required due to respiratory failure from residual blockade and pharmacologic reversal with `J2711` is part of the intervention.

OpenPayer

Summary & Overview

HCPCS J2711: Neostigmine and Glycopyrrolate Injection 0.1 mg / 0.02 mg